Current Edition

Upcoming Events

Advertisement

news

GSK wagers $2.1B on Affinivax and its next-generation pneumonia vaccine

GSK has agreed to acquire Affinivax in a deal announced Tuesday, betting more than $3 billion that the eight-year-old startup’s technology can lead to a more effectiv...
Continue Reading →
news

Pfizer to exit GSK consumer health joint venture after spinoff

Dive Brief: Pfizer plans to sell its shares in a consumer health joint venture with GlaxoSmithKline after the business is spun off into a new standalone corporatio...
Continue Reading →
news

Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs

Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a big bet on it...
Continue Reading →
news

UK bid to battle antibiotic resistance yields first subscription-style plan

The U.K. took a small step forward in its efforts to spur development of new antibiotics, announcing on Tuesday a plan to pay Pfizer and Shionogi roughly $13 million ...
Continue Reading →
news

Pfizer buys a private biotech and its RSV drug research

Dive Brief: Pfizer said Thursday it will spend as much as $525 million to buy the privately held biotech ReViral, adding experimental treatments for respiratory sy...
Continue Reading →
news

Pfizer claims study success for drug key to Arena buyout

Dive Brief: Pfizer said Wednesday an experimental drug central to its $7 billion purchase of Arena Pharmaceuticals succeeded in a crucial Phase 3 trial in patients...
Continue Reading →
news

Alnylam sues Pfizer, Moderna over technology used in COVID vaccines

Dive Brief: Alnylam is accusing Pfizer and Moderna of violating a patent it holds for technology that Alnylam claims the two companies use in their respective COVI...
Continue Reading →
news

Moderna, citing need for ‘flexibility,’ seeks broad clearance of fourth COVID shot

Dive Brief: Moderna has asked the Food and Drug Administration to clear a fourth dose of its COVID-19 vaccine for adults 18 and over, a broader request than Pfizer...
Continue Reading →
news

After slower-than-expected review, Pfizer and Arena close buyout deal

Dive Brief: Arena Pharmaceuticals' $7 billion sale to Pfizer closed on Friday, ending a slightly protracted regulatory review that raised questions about whether t...
Continue Reading →
news

Pfizer forecasts $100B in sales, fueled by COVID-19 vaccine, pill

Dive Brief: Pfizer on Tuesday forecast that its revenue this year will grow to total between $98 billion and $102 billion, which, measured at the range's midpoint,...
Continue Reading →